'High-priced Poker Game'

Apr 20, 2012

GlaxoSmithKline has made a $2.6 billion unsolicited offer to take over Human Genome Sciences, reports Brett Chase at Miyanville. But not only has Human Genome rejected Glaxo's offer, it put itself up for sale to the highest bidder, saying Glaxo's offer of $13 a share is too low and doesn't reflect the potential value of the company.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Memo Roll Back

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.

Great, Now a Swine Flu Strain

Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.

Samples All Together

The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.

Genome Research Studies Explore Y Chromosome Expression, Mutations From Aging Macaque Dads, More

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.

Menu